Ultragenyx Pharmaceutical (NASDAQ:RARE) Earns Overweight Rating from Cantor Fitzgerald
Cantor Fitzgerald reiterated their overweight rating on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE – Free Report) in a research report report published on Wednesday, Benzinga reports. The firm currently has a $115.00 price target on the biopharmaceutical company’s stock. Other analysts also recently issued reports about the company. The Goldman Sachs Group raised Ultragenyx Pharmaceutical from […]
More Stories
Vital Energy (NYSE:VTLE) & Diversified Energy (NYSE:DEC) Head to Head Analysis
Vital Energy (NYSE:VTLE – Get Free Report) and Diversified Energy (NYSE:DEC – Get Free Report) are both small-cap oils/energy companies,...
Head-To-Head Comparison: Connectm Technology Solutions (NASDAQ:CNTM) vs. Brookfield Business Partners (NYSE:BBU)
Connectm Technology Solutions (NASDAQ:CNTM – Get Free Report) and Brookfield Business Partners (NYSE:BBU – Get Free Report) are both small-cap...
Secure Energy Services Inc. (TSE:SES) Given Average Rating of “Moderate Buy” by Analysts
Secure Energy Services Inc. (TSE:SES – Get Free Report) has been given an average recommendation of “Moderate Buy” by the...
Contrasting Apple Hospitality REIT (NYSE:APLE) & Plymouth Industrial REIT (NYSE:PLYM)
Apple Hospitality REIT (NYSE:APLE – Get Free Report) and Plymouth Industrial REIT (NYSE:PLYM – Get Free Report) are both finance...
Analysts Set ServiceTitan Inc. (NASDAQ:TTAN) Target Price at $117.00
ServiceTitan Inc. (NASDAQ:TTAN – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the fourteen brokerages...
HIVE Digital Technologies (NASDAQ:HIVE) vs. Crescent Capital BDC (NASDAQ:CCAP) Financial Survey
Crescent Capital BDC (NASDAQ:CCAP – Get Free Report) and HIVE Digital Technologies (NASDAQ:HIVE – Get Free Report) are both small-cap...